As destabilizing menin mutations are reported across multiple NET types (28–30) and in other malignancies, including gastric cancer (49), a large-scale clinical investigation is warranted to determine whether menin protein stability may be associated with clinical phenotype or aggressiveness of disease. The gene discussed is MEN1; the disease is gastric cancer.